CSF neurogranin levels as a biomarker in Alzheimer’s disease and frontotemporal lobar degeneration: a cross-sectional analysis
In this first study to-date to assess MCI and dementia due to AD or FTLD within one study, elevated CSF Ng appears to be an early biomarker of AD-related impairment, but its role as a biomarker appears to diminish after dementia diagnosis, whereby dementia-related underlying processes in AD and FTLD may begin to merge. The Aβ<sub>1-42</sub>/Ng ratio discriminated AD from FTLD patients better than Ng alone. CSF Ng levels were not related to memory in AD or FTLD, suggesting that Ng may be a marker of the biological signs of disease state rather than cognitive deficits.
Authors
- Tereza Kolářová
- Alžběta Katonová (ORCID: https://orcid.org/0009-0006-5605-7200)
- Kaj Blennow (ORCID: https://orcid.org/0000-0002-1890-4193)
- Hana Horáková (ORCID: https://orcid.org/0000-0003-4192-1423)
- Martin Vyhnálek (ORCID: https://orcid.org/0000-0002-5976-4932)
- Kateřina Veverová (ORCID: https://orcid.org/0000-0002-5845-1854)
- Ross Andel (ORCID: https://orcid.org/0000-0003-4083-4790)
- Jakub Hort (ORCID: https://orcid.org/0000-0002-1080-3726)
- Terezie Zuntychova
- Vanesa Jurasova
- Václav Maťoška (ORCID: https://orcid.org/0009-0005-3459-6193)
Institutions
- Charles University (CZ)
- Sahlgrenska University Hospital (SE)
- University Hospital in Motol (CZ)
- University Hospital Brno (CZ)
- Na Homolce Hospital (CZ)
- St. Anne's University Hospital Brno (CZ)
- Arizona State University (US)
- University of Gothenburg (SE)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1186/s13195-024-01566-w
- Citations
- 9
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 3.47
Funders
- Univerzita Karlova v Praze
- Grantová Agentura, Univerzita Karlova
- European Commission